ATAI Investor Day Presentation Deck

CIAS phase 2a: study schematic Evaluate independent cohorts dosed with 10, 20, 40, or 80 mg TID (5 doses TID reaches approximate CSF steady state) atai LIFE SCIENCES ● ● Screening 1-45 days Day: -1 In-patient at CRU PBO ECG Labs C-SSRS 1 RL-007 2 qEEG/ERP Cog. ECG Labs qEEG/ERP Cog. C-SSRS 3 4 Placebo dosing ◆RL-007 dosing 5 A single-center, single-arm, single blind, multiple dose study Schizophrenia patients stable on a protocol-allowed antipsychotic Patients blinded to the dose strength & sequence of active/placebo dosing Single site study - Collaborative Neuroscience Research, Dr. David Walling (PI) 8 Phone call, Exit C-SSRS 134

View entire presentation